Update on Generalized Pustular Psoriasis

Area of Science:

• Dermatology
• Immunology
• Genetics

Background:

• Generalized pustular psoriasis (GPP) is a severe, rare inflammatory skin disease.
• GPP is distinct from plaque psoriasis, with unique clinicopathological, immunologic, and genetic profiles.
• The IL-36 pathway and IL36RN gene mutations are key to GPP pathogenesis.

Purpose of the Study:

• To provide a comprehensive overview of GPP.
• To discuss epidemiology, pathophysiology, clinical features, comorbidities, and treatment strategies.
• To highlight recent advances in targeted GPP therapies.

Main Methods:

• Narrative review of existing literature.
• Analysis of GPP pathogenesis, focusing on the IL-36 pathway.
• Evaluation of diagnostic criteria and disease severity assessment.

Main Results:

• GPP diagnosis requires integrated clinical, histopathologic, and laboratory data.
• GPP flares can cause severe systemic complications, including sepsis and multi-organ failure.
• Spesolimab is the first targeted therapy approved for GPP flares in Europe and the USA.

Conclusions:

• GPP management is complex, necessitating a thorough understanding of its distinct features.
• Targeted therapies based on IL-36 pathway dysregulation represent a significant advancement.
• Continued research is crucial for optimizing GPP treatment strategies.